[Pustular psoriasis, palmoplantar psoriasis, erythodermal psoriasis and etanercept].
Etanercept has been approved for the treatment of moderate-severe plaque psoriasis. This is the most frequent form of psoriasis (80%). In other forms of psoriasis, the use of etanercept, as that of other biological therapies, has been published in an isolated way with satisfactory results. We present a patient with palmoplantar pustulous psoriasis palmoplantar refractory to multiple treatments (topical corticosteroids, phototherapy, methotrexate) who responded favorably to the use of 50 mg biweekly doses of etanercept. The patient has maintained total remission of the lesions 6 months after having terminated treatment. We review the cases published on palmoplantar psoriasis treated with etanercept and also the use of this drug in other forms of pustular psoriasis and of erythrodermal psoriasis.
López-Estebaranz
J L
JL
Servicio de Dermatología, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, España. jllopez@fhalcorcon.es
Ruiz-Genao
D
D
D000328:Adult; D003873:Dermatitis, Exfoliative / Q000188:drug therapy*; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G; D011565:Psoriasis / Q000188:drug therapy*; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept